Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
5.07
-0.21 (-3.98%)
Nov 21, 2024, 11:08 AM EST - Market open
Outlook Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
24
Market Cap
119.93M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Well | 254.04M |
| Repare Therapeutics | 66.52M |
| Compugen | 59.85M |
| Protalix BioTherapeutics | 45.67M |
| Zomedica | 26.73M |
| Cibus | 4.15M |
| Avalo Therapeutics | 820.00K |
OTLK News
- 15 days ago - Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles - Seeking Alpha
- 3 months ago - Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - GlobeNewsWire